Michael Fischbach Ph.D.
Dr. Fischbach has served on Achaogen’s board of directors since November 2015. In 2017, Dr. Fischbach joined Stanford University as an Associate Professor in the Department of Bioengineering and as a member of Stanford ChEM-H, an interdisciplinary research institute that uses chemistry, engineering and medicine to improve human health. Dr. Fischbach’s laboratory uses a combination of genomics and chemistry to identify and characterize small molecules from microbes, with an emphasis on the human microbiome. Prior to Stanford, he was an Associate Professor in the Department of Bioengineering and Therapeutic Sciences at UCSF, and prior to that he spent two years as an independent fellow at Massachusetts General Hospital. He is a member of the California Institute for Quantitative Biosciences (QB3). Dr. Fischbach is a recipient of the NIH Director's Pioneer and New Innovator Awards, an HHMI-Simons Faculty Scholars Award, a Fellowship for Science and Engineering from the David and Lucille Packard Foundation, a Medical Research Award from the W.M. Keck Foundation, a Burroughs Wellcome Fund Investigators in the Pathogenesis of Infectious Disease award, and a Glenn Award for Research in Biological Mechanisms of Aging. Dr. Fischbach received his Ph.D. as a John and Fannie Hertz Foundation Fellow in chemistry from Harvard in 2007 and earned his A.B. in Biochemistry from Harvard.
Dr. Fischbach is a member of the scientific advisory boards of NGM Biopharmaceuticals, Cell Design Labs, and Indigo Agriculture, and is a co-founder of Revolution Medicines.